A Phase 1 interventional study of 14C-SEP-380135 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 108th largest by planned enrollment of the 111 interventional ones that give a count, is the only one that started in 2026, is one of 34 in phase 1, and was the 119th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–74
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 14 · Phase 3 54 · Phase 4 13
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 125 across the 111 interventional studies, 281 across the 8 observational. Of the 111 that completed or were terminated, 64 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
2 of the studies in Schizophrenia by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05325645Phase 3Otsuka Pharmaceutical Co., Ltd.Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | 2027-09 |
| NCT07455084Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | 2026-12-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In good overall health, based on:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral administration of 14C-SEP-380135 on Day 1.
Drug: 14C-SEP-380135
Oral Capsule
Total Radioactivity Amount Excreted in Urine (Ae,u)
Time frame: Up to Day 8
Total Radioactivity Amount Excreted in Feces (Ae,f)
Time frame: Up to Day 8
Fraction of Dose Excreted in Urine (%fe,u)
Time frame: Up to Day 8
Fraction of Dose Excreted in Feces (%fe,f)
Time frame: Up to Day 8
Maximum Plasma Concentration (Cmax) of SEP-380135 and Metabolites
Time frame: Up to Day 8
Time for Cmax (tmax) of SEP-380135 and Metabolites
Time frame: Up to Day 8
Area Under the Concentration-Time Curve From Time Zero to the Last Observable Concentration at Time (AUCt) of SEP-380135 and Metabolites
Time frame: Up to Day 8
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of SEP-380135 and Metabolites
Time frame: Up to Day 8
Elimination Half-Life (t1/2,z) of SEP-380135 and Metabolites
Time frame: Up to Day 8
Apparent Clearance of Drug From Plasma After Oral Administration (CL/F) of SEP-380135
Time frame: Up to Day 8
Apparent Clearance of Drug From Plasma After Oral Administration Adjusted for Body Weight (CL/F/BW) of SEP-380135
Time frame: Up to Day 8
Volume of Distribution Following Oral Administration (Vz/F) of SEP-380135
Time frame: Up to Day 8
Number of Participants with Adverse Events (AEs)
Time frame: Up to Day 31
Number of Participants with Potentially Clinically Significant Changes in Vital Signs
Time frame: Upto Day 8
Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Time frame: Upto Day 8
Number of Participants With Potentially Clinically Significant Changes in Physical Examinations
Time frame: Upto Day 8
Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters
Time frame: Upto Day 8
Number of Participants With Incidence of Suicidal Ideation and Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Upto Day 8
Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 1 month is below that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Mar 2026 → Nov 2026, primary completion Apr 2026 → Dec 2026 and completion May 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc. →